450 related articles for article (PubMed ID: 25107680)
21. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
[TBL] [Abstract][Full Text] [Related]
22. Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
Pillsbury AJ; Quinn HE; Evans TD; McIntyre PB; Brotherton JML
Clin Infect Dis; 2017 Sep; 65(5):827-832. PubMed ID: 29017279
[TBL] [Abstract][Full Text] [Related]
23. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening.
Shilling H; Murray G; Brotherton JML; Hawkes D; Saville M; Sivertsen T; Chambers I; Roberts J; Farnsworth A; Garland SM; Hocking JS; Kaldor J; Guy R; Atchison S; Costa AM; Molano M; Machalek DA
Vaccine; 2020 Jan; 38(5):1186-1193. PubMed ID: 31767467
[TBL] [Abstract][Full Text] [Related]
24. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.
Korostil IA; Peters GW; Law MG; Regan DG
Vaccine; 2013 Apr; 31(15):1931-6. PubMed ID: 23434388
[TBL] [Abstract][Full Text] [Related]
25. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
26. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs in Young Women in the United States Between 2003 and 2012.
Tarney CM; Klaric J; Beltran T; Pagan M; Han J
Obstet Gynecol; 2016 Dec; 128(6):1241-1247. PubMed ID: 27824760
[TBL] [Abstract][Full Text] [Related]
28. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
[TBL] [Abstract][Full Text] [Related]
29. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women.
Spinner C; Ding L; Bernstein DI; Brown DR; Franco EL; Covert C; Kahn JA
Pediatrics; 2019 Feb; 143(2):. PubMed ID: 30670582
[TBL] [Abstract][Full Text] [Related]
30. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
[TBL] [Abstract][Full Text] [Related]
32. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
34. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.
Malagón T; Laurie C; Franco EL
Expert Rev Vaccines; 2018 May; 17(5):395-409. PubMed ID: 29715059
[TBL] [Abstract][Full Text] [Related]
35. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
36. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
37. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
J Infect Dis; 2017 Sep; 216(5):594-603. PubMed ID: 28931217
[TBL] [Abstract][Full Text] [Related]
40. Postlicensure monitoring of HPV vaccination programmes.
Markowitz LE; Hariri S
Lancet Infect Dis; 2014 Oct; 14(10):904-5. PubMed ID: 25107681
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
